Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

250
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
250
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

223
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
223
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

270
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
270
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

295
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
295
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

2.1K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.1K
Liver Physiology01:30

Liver Physiology

3.9K
The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of  70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intestinal neutral ceramidase exacerbates MASH pathogenesis.

eGastroenterology·2026
Same author

Illustration of the gut-immune-liver axis in early-stage alcohol-related liver disease: role and non-invasive potentiation of biomarkers and peptidomic signatures.

Npj gut and liver·2026
Same author

Sparse CCA-Based Mediation Analysis with High-Dimensional Exposures and Mediators.

Bioinformatics (Oxford, England)·2026
Same author

Dietary fructose promotes MASH/HCC progression through enhanced intestinal HIF-2α-dependent iron absorption.

bioRxiv : the preprint server for biology·2026
Same author

Mean Arterial Pressure at Admission Predicts 28-day Mortality in Patients with Severe Alcohol-associated Hepatitis.

Clinical and translational gastroenterology·2026
Same author

Loss of BATF3 impairs adipose-liver homeostasis and accelerates the transition from steatosis to fibrosis in high-fat diet-fed mice.

International journal of biological sciences·2026

Related Experiment Video

Updated: Feb 21, 2026

Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders
06:52

Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders

Published on: April 28, 2023

2.0K

Zinc and liver disease.

Mohammad K Mohammad1, Mohammad K Mohommad, Zhanxiang Zhou

  • 1University of Louisville, Louisville, KY, USA.

Nutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition
|February 7, 2012
PubMed
Summary

Zinc is vital for cell growth and function. In liver disease, zinc deficiency is common, but supplementation may improve liver function and reverse deficiency symptoms.

More Related Videos

Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides
11:04

Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides

Published on: September 7, 2019

9.9K
Atomic Absorbance Spectroscopy to Measure Intracellular Zinc Pools in Mammalian Cells
13:04

Atomic Absorbance Spectroscopy to Measure Intracellular Zinc Pools in Mammalian Cells

Published on: May 16, 2019

39.3K

Related Experiment Videos

Last Updated: Feb 21, 2026

Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders
06:52

Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders

Published on: April 28, 2023

2.0K
Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides
11:04

Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides

Published on: September 7, 2019

9.9K
Atomic Absorbance Spectroscopy to Measure Intracellular Zinc Pools in Mammalian Cells
13:04

Atomic Absorbance Spectroscopy to Measure Intracellular Zinc Pools in Mammalian Cells

Published on: May 16, 2019

39.3K

Area of Science:

  • Biochemistry
  • Hepatology
  • Nutritional Science

Background:

  • Zinc is an essential trace element crucial for cellular processes like DNA synthesis and cell division.
  • Zinc deficiency or altered metabolism is frequently observed in various liver diseases, including alcoholic liver disease (ALD) and viral hepatitis.
  • Mechanisms of zinc deficiency in liver disease include reduced intake, increased excretion, altered transporter activity, and metallothionein induction.

Purpose of the Study:

  • To review the role of zinc in liver disease.
  • To explore the effects of zinc supplementation on liver disease, particularly ALD and viral hepatitis.
  • To discuss the clinical implications and recommended dosage of zinc supplementation for liver disease patients.

Main Methods:

  • Literature review of zinc's role in cellular functions and liver disease pathophysiology.
  • Analysis of studies investigating zinc deficiency mechanisms in liver disease.
  • Evaluation of experimental and clinical trial data on zinc supplementation in liver disease.

Main Results:

  • Zinc deficiency can manifest as skin lesions, impaired wound healing, cognitive changes, and immune dysfunction in liver disease patients.
  • Experimental studies show zinc supplementation can protect against ALD by improving gut barrier function, reducing endotoxemia, inflammation, oxidative stress, and hepatocyte apoptosis.
  • Clinical trials, though limited, indicate zinc supplementation corrects deficiency signs and may improve liver function and fibrosis markers in patients with ALD and hepatitis C.

Conclusions:

  • Zinc plays a critical role in maintaining liver health, and deficiency is a significant concern in liver disease.
  • Zinc supplementation demonstrates therapeutic potential in mitigating liver disease progression and symptoms, particularly in ALD and viral hepatitis.
  • While further high-quality clinical trials are needed, current evidence supports zinc supplementation (typically 50 mg elemental zinc with meals) for patients with liver disease to address deficiency and potentially improve outcomes.